Houston, United States
OncoResponse, founded in 2016, is an innovative player in the immuno-oncology biotech sector. This biopharma company is particularly notable for its strategic collaboration with the MD Anderson Cancer Center, which amplifies its capabilities in treating cancer.
Utilizing a proprietary B-cell discovery platform, OncoResponse is adept at developing novel therapeutics designed to target the tumor microenvironment. Their lead candidate, OR2805, is progressing through clinical trials, presenting a transformative approach to cancer treatment. This progress positions the company as a potential game-changer in advancing cancer therapeutics.
Headquartered in both Houston, Texas and Seattle, Washington, OncoResponse attracts significant attention from major investors. Its latest funding of $14.00 million in May 2023, secured from a consortium of respected investors, such as Arch Venture Partners and Takeda Ventures, enhances its financial runway to continue groundbreaking innovation in United States-based research.
